Anxiety disorders, major depressive disorder and the dynamic relationship between these conditions: Treatment patterns and cost analysis

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 99-109

  François, Clément ^a,b   Despiégel, Nicolas ^b   Maman, Khaled ^c   Saragoussi, Delphine ^b   Auquier, Pascal ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Lundbeck   (France)

^c Altipharm   (France)

Author keywords

Anxiety; Comorbidity; Cost; Database; Healthcare resource use; Major depressive disorder

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA BASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; REIMBURSEMENT; RETROSPECTIVE STUDY; SOCIAL PHOBIA; UNITED STATES;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES; HEALTH STATUS INDICATORS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; UNITED STATES;

EID: 77149129579     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696991003591321     Document Type: Article

References (23)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
2. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
3. de Graaf R, Bijl RV, Smit F, et al. Risk factors for 12-month comorbidity of mood, anxiety, and substance use disorders: findings from the Netherlands Mental Health Survey and Incidence Study. Am J Psychiatry 2002;159:620-629
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
5. DuPont RL, Rice DP, Miller LS, et al. Economic costs of anxiety disorders. Anxiety 1996;2:167-172
6. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427-435
7. Wang PS, Aguilar-Gaxiola S, Alonso J, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet 2007;370:841-850
8. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:629-640
9. Konnopka A, Leichsenring F, Leibing E, et al. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord 2009;114:14-31
10. Stein MB, Cantrell CR, Sokol MC, et al. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 2006;57:673-680
11. McLaughlin TP, Khandker RK, Kruzikas DT, et al. Overlap of anxiety and depression in a managed care population: Prevalence and association with resource utilization. J Clin Psychiatry 2006;67:1187-1193
12. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
13. OECD. Country statistical profiles 2009: United States. 2009 [updated 2009; cited 2009 November 30]; Available from: http://stats.oecd.org/index.aspx? queryid=18175
14. Blough DK, Ramsey SD. Using Generalized Linear Models to Assess Medical Care Costs. Health Services and Outcomes Research Methodology 2000;1:185-202
15. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494
16. Norberg MM, Calamari JE, Cohen RJ, et al. Quality of life in obsessive-compulsive disorder: an evaluation of impairment and a preliminary analysis of the ameliorating effects of treatment. Depress Anxiety 2008;25:248-259
17. Schultz LT, Heimberg RG, Rodebaugh TL, et al. The appraisal of social concerns scale: psychometric validation with a clinical sample of patients with social anxiety disorder. Behav Ther 2006;37:392-405
18. Lipsitz JD, Schneier FR. Social phobia. Epidemiology and cost of illness. Pharmacoeconomics 2000;18:23-32
19. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006;51:9-91S
20. Simon GE, Chisholm D, Treglia M, et al. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002;24:328-335
21. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008;25:72-90
22. Marciniak MD, Lage MJ, Dunayevich E, et al. The cost of treating anxiety: the medical and demographic correlates that impact total medical costs. Depress Anxiety 2005;21:178-184
23. Zhu B, Zhao Z, Ye W, et al. The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J NervMent Dis 2009;197:136-139